| 000 | 02018cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031105.0 | ||
| 008 | 141112s2014 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.11.07.Ph.D.2014.La.L | ||
| 100 | 0 | _aLamiaa Mohammad kamal | |
| 245 | 1 | 0 |
_aLeukemic stem cell enumeration in acute myeloid leukemia : _bRelation to prognosis / _cLamiaa Mohammad kamal ; Supervised Iman Maher Mansour , Nahed Abdelwahab Mohammad , Lobna Ossama Elmeseery |
| 246 | 1 | 5 | _aتعداد الخلايا الجذعية اللوكيميه في اللوكيميا النقيانيه الحاده وبيان العلاقه بعاقبة المرض |
| 260 |
_aCairo : _bLamiaa Mohammad kamal , _c2014 |
||
| 300 |
_a137 P. : _bcharts ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology | ||
| 520 | _a The poor response to therapy in acute myeloid leukemia (AML) raises the expectations that the presence of leukemic stem cells (LSCs) may add to therapy resistance. Using flowcytometry, we analyzed the expression of CD123 among CD34+CD38- cells in AML patients at initial diagnosis and on day 14 post induction. We concluded thatCD123 may be used as marker of LSCs in AML, presence of LSCs at diagnosis had no prognostic impact on treatment outcome and the emergence of LSCs in post induction samples may reflect an induced stem cell theory contributing further to disease resistance | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAcute myeloid leukemia | |
| 653 | 4 | _aInterleukin 3 receptor alpha chain | |
| 653 | 4 | _aLeukemic stem cell | |
| 700 | 0 |
_aIman Maher Mansour , _eSupervisor |
|
| 700 | 0 |
_aLobna Ossama Elmeseery , _eSupervisor |
|
| 700 | 0 |
_aNahed Abdelwahab Mohammad , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aAml _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c48196 _d48196 |
||